CPP clinical trials are testing the exploitation of key pathways implicated in cancer risk: polyamine synthesis and inflammation.
Our lead product, CPP-1X, decreases polymine synthesis and in combo therapy with sulindac (CPP-1X/sul) also increases polymine elimination and reduces inflammation which has an important effect on the pathway of several diseases.
CPP-1X/sul is now in multiple clinical trials:
CPP is sponsoring the FAP-310 Pivotal Phase 3 Trial of CPP-1X/sul for Familial Adenomatous Polyposis. All patients have completed treatment and results are expected in the first quarter of 2019.
Funded by NCI and in collaboration with SWOG, the PACES Phase 3 Trial of CPP-1X/sul for colon adenomas is now recruiting patients.
Additional clinical and preclinical studies are ongoing for gastric cancer, pancreatic cancer, and early-onset type 1 diabetes.